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Edited by Laszlo NagyAbstract Peroxisome proliferator-activated receptor gamma
coactivator-1 alpha (PGC-1a), a highly inducible transcriptional
coactivator regulating energy homeostasis, is down-regulated in
hepatoma tissues. To dissect its role in hepato-tumorigenesis,
Ingenuity Pathway Analysis was applied to construct pathways
aﬀected by PGC-1a upregulation in HepG2 hepatoma cells
based on our microarray data. Interestingly, migration of these
cells was markedly diminished by PGC-1a overexpression in
consistency with Ingenuity results. Moreover, a deduced
expression increase of E-cadherin was also observed in PGC-
1a-overexpressing HepG2 cells. Finally, transient transfection
and chromatin-immunoprecipitation assays suggested that in-
creased histone acetylation might be responsible for PGC-1a-
mediated transactivation of a minimal E-cadherin promoter.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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PGC-1a was ﬁrst identiﬁed as a peroxisome proliferator-
activated receptor gamma (PPARc)-interacting protein that
regulates adaptive thermogenesis in murine [1]. Human
PGC-1a was ﬁrst described by Esterbauer et al. as a potential
regulator of insulin sensitivity [2]. This energy-athirst induced
transcription coactivator is highly responsive to a variety of
environmental cues, including temperature changes, nutri-
tional status and physical activity where it cooperates withAbbreviations: ChIP, chromatin-immunoprecipitation; GFP, green
ﬂuorescence protein; HAT, histone acetyltransferase; HCC, hepato-
cellular carcinoma; MOI, multiplicity of infection; PGC-1a, peroxi-
some proliferator-activated receptor gamma coactivator-1 alpha;
PPAR, peroxisome proliferator-activated receptor; ROS, reactive
oxygen species; SEAP, secreted alkaline phosphatase
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doi:10.1016/j.febslet.2008.01.033nuclear receptors in a tissue-speciﬁc manner [3]. Therefore,
various diseases with underlying dysregulation of metabolism
may occur because of aberrant PGC-1a expression [4].
Cancer cells preferentially utilize glycolytic pathways for
energy generation while down-regulating their aerobic respira-
tory activity, known as the ‘‘Warburg eﬀect’’ [5]. In other
words, tumor cells may have impaired mitochondrial function
which results in an elevation of glycolytic ATP generation and
a simultaneous decrease of oxidative phosphorylation [6,7]. In
a previous study, we demonstrated that PGC-1a expression,
the copy number of mitochondrial DNA and the content of
mitochondrial respiratory proteins were reduced in hepato-
cellular carcinoma (HCC) as compared with the adjacent
non-tumorous tissues [8], suggesting that dysregulated expres-
sion of this transcription coactivator may be involved in
hepatocarcinogenesis.
By docking on several nuclear receptors, PGC-1a greatly
enhances their transcriptional activity through the recruitment
of histone acetyltransferase (HAT)-containing proteins as well
as interacting with RNA polymerase II complex [9,10]. Among
the nuclear partners of PGC-1a, PPARc has been shown to
inhibit the growth of a variety of cancer cells including breast,
colon, prostate and liver [11]. The malignancy suppressive
eﬀect of PPARc agonists has been postulated to result from
an increased expression of E-cadherin [12,13], a transmem-
brane protein of the adherens junctions that mediates cell–cell
interaction which is involved in the morphogenesis and estab-
lishment of tissues [14]. While a loss of E-cadherin expression
has been reported to be correlated with the progression of non-
invasive tumor cells into malignant, metastatic carcinomas
including HCC [14,15], reintroduction or upregulation of this
cell adhesion molecule has been shown to suppress the
in vivo [16] and in vitro invasion of tumor cells [17]. These
results together emphasize that PPARc pathway upregulated
E-cadherin expression plays a crucial role in suppressing tumor
progression.
The decrease of PGC-1a is linked to the variation of PPARc
expression level in breast cancer [18] and ovarian cancer cells
[19]; however, the potential role of PGC-1a in the pathogenesis
of liver cancer remains to be examined. Here, we transduced
PGC-1a into human hepatoma HepG2 cells and employed
cDNA microarray analysis to dissect the role of this transcrip-
tion coactivator in regulation of cellular function in hepatoma
cells. Our results suggested that PGC-1a upregulation isblished by Elsevier B.V. All rights reserved.
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over, a unique ﬁnding in transcriptional regulation of E-cad-
herin by PGC-1a in HepG2 cells was described and
discussed in details.2. Materials and methods
2.1. Cell culture
HepG2 human hepatoblastoma cells were grown in Dulbeccos mod-
iﬁed Eagles medium (DMEM) supplemented with 10% fetal bovine
serum, 10 lg/ml gentamycin, 2 mM L-glutamine, 0.1 mM non-essential
amino acid at 37 C in a humidiﬁed atmosphere containing 5% CO2.
Cell growth was determined by trypan blue exclusion assay.
2.2. Construction of the recombinant adenoviral genome and production
of Ad-PGC-1a virus
Full length PGC-1a cDNA fragment was ampliﬁed by PCR from
HepG2 cDNA. Ad-PGC-1a virus was produced according to manu-
facturers protocol (AdEasy XL Adenoviral vector system; Strata-
gene, La Jolla, CA). Large preparation of virus and its infection in
HepG2 cells were performed as described previously [20].
2.3. Microarray analysis and pathway identiﬁcation
Total RNA was isolated from 2 days post-infected HepG2 cells
using Trizol reagent (Invitrogene, Carlsbad, CA). RNA samples were
processed for hybridization on Aﬀymetrix Human Genome U133 plus
2.0 gene chips (Aﬀymetrix, Santa Clara, CA). The diﬀerentially
expressed (>2-fold) probe sets were overlaid on a cellular pathway
map in the Ingenuity Pathway Analysis.
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis
Total RNA and cDNA was prepared as described previously [8].
PCR primer sets were: for PGC-1a, sense: 5 0-CCAAATGACCCCAA-
GGGTTC-30 and antisense: 5 0-TATGAGGAGGAGTGGTGGGTG-
3 0; for glucose-6-phosphatase (G6Pase), sense: 5 0-GACTCCCAGGA-
CTGGTTCATC-30 and antisense: 5 0-TCAGCTGCACAGCCCAGA-
ATC-3 0; for carnitine palmitoyltransferase I (CPTI), sense: 5 0-CAA-
GGTCTGGCTCTACCATG-3 0 and antisense: 5 0-GACTTGTC-
AAACCACCTGTCG-3 0; for cytochrome c (Cyt. c), sense: 5 0-GAT-
GGAGTATTTGGAGAATCC-3 0 and antisense: 5 0-GATCTGAA-
TTCTGGTGTATGAG-3 0; for E-cadherin, sense: 5 0-CAGCCTGTC
GAAGCAGGATTGC-3 0 and antisense: 5 0-GAGCTCAGACTA-
GCAGCTTCGG-3 0; for b-actin, sense: 5 0-TGGCATTGCCGACAG-
GAT-3 0 and antisense: 5 0-GCTCAGGAGGAGCAATGATCT-30.
SyBr green intercalating real-time quantitative PCR (qPCR) was
performed by ABI PRISM 7700 (PE Applied Biosystems, Foster city,
CA). E-cadherin primer sets for qPCR were sense: 5 0-TGAAGG-
TGACAGAGCCTCTGGAT-30 and antisense: 5 0-TGGGTGAATTC-
GGGCTTGTT-3 0.
2.5. Western blot analysis
Cells were harvested 3 days post-infection and Western blotting was
performed as described previously [21] using the following antibodies:
PGC-1a, cytochrome c (Santa Cruz Biotechnology Inc., Santa Cruz,
CA), cyclin D1, E-cadherin (BD Biosciences, San Diego, CA) and
b-actin (Sigma, Saint Louis, MO).
2.6. Immunoﬂuorescence staining and confocal imaging
Infected cells were grown on coverslips for 48 h, then performed
immunoﬂuorescence double staining using PGC-1a and E-cadherin
antibodies as described previously [21]. A confocal microscope (Zeiss
inverted, Axiovert 200M) with a dip in lens Plan Fluor objective
(·100 oil) was used. Images were acquired using LSM 5 PASCAL soft-
ware.
2.7. Transwell cell migration analysis
Two days post-infection cells (1 · 105) were added to 8 lm pore size
non-coated transwell top chambers (Corning Costar, Acton, MA) and
mobility analysis was performed as described previously [21].2.8. E-cadherin promoter derived secreted alkaline phosphatase (SEAP)
reporter gene construction and SEAP reporter activity analysis
Human E-cadherin promoter 1001 to +67 fragment phE-cad(-1kb)
was obtained by PCR ampliﬁcation of the genomic DNA prepared
from human HepG2 cells and inserted into pSEAP2-Basic (Clontech
Laboratories, Inc., Mountain View, CA). The serial deletion mutant
fragments were ampliﬁed by PCR from phE-cad(-1kb). SEAP activity
assay was performed as described previously [22].
2.9. Chromatin-immunoprecipitations (ChIPs)
DNA–protein complex was cross-linked two day post-infection;
chromatin was sheared by sonication (4 W, 4 s; break, 10 s for 30 times
on ice). The following analysis was performed by Chromatin Immuno-
precipitation Assay Kit (Upstate, Lake Placid, NY) according to
manufacturers recommendation. E-cadherin promoter fragment
ampliﬁcation was performed by nested-PCR using the following
primer sets: 1st – sense, pE-cad(-239)-F, 5 0-GGATTCGAACCCA-
GTGGAATCAG-3 0; antisense, pE-cad(+67)-R, 5 0-CTGGAGCGGG-
CTGGAGTCTGAACTGAC-3 0; 2nd – sense, pE-cad(-192)-F,
5 0-CTAGACCCTAGCAACTCCAG-30; antisense, pE-cad(+9)-R,
5 0-GACGCCACTGAGAGG-3 0.
2.10. Statistical analysis
Arithmetic means and standard deviations (S.D.) were obtained
from three independent experiments, and statistical signiﬁcance was
considered when P < 0.05 using Students t-test.3. Results
3.1. PGC-1a transduced by recombinant adenovirus is functional
in HepG2 cells
To identify genes whose expression in hepatocyte might be
aﬀected by PGC-1a upregulation, recombinant adenovirus
carrying the corresponding gene (Ad-PGC-1a) was generated
and used to infect HepG2 cells. Expression of several well-
known PGC-1a-inducible genes including glucose-6-phospha-
tase (G6Pase), carnitine palmitoyl transferase I (CPTI) and
cytochrome c (Cyt. c) was examined by RT-PCR analysis.
As shown in Fig. 1a, all three genes were induced by PGC-
1a upregulation. Fig. 1b shows that the growth of HepG2 cells
was not altered by PGC-1a overexpression in the ﬁrst 2 days
post-infection but slightly decreased on day 3. Overexpression
of PGC-1a did not induce apoptosis of HepG2 cells (data not
shown). Fig. 1c shows that the expression of cyclin D1 protein
was reduced in PGC-1a-overexpressing cells at the same time.
3.2. Assessment of the pathways in HepG2 cells inﬂuenced by
PGC-1a upregulation
Having validated the eﬀects of PGC-1a overexpression in
HepG2 cells, we then used microarray analysis to identify
more thoroughly its target genes. In comparison with cells
infected by the control virus (Ad-green ﬂuorescence protein
(GFP)), Ad-PGC-1a-infected cells exhibited diﬀerent expres-
sion patterns in genes mainly involved in energy homeostasis
such as gluconeogenesis, lipid metabolism and mitochondrial
respiration (Fig. 2a). After reconstruction of the pathway
networks by Ingenuity Pathway Analysis, we found that the
altered pathway with second highest score was associated with
cancer and cellular movement (Fig. 2b).
3.3. PGC-1a overexpression decreases migration ability of
HepG2 cells
Since cellular movement has been suggested to be aﬀected
by PGC-1a overexpression, transwell migration analysis was
Fig. 1. Eﬀects of PGC-1a transactivation on energy metabolism
related genes and cell proliferation in HepG2 cells. (a) Semi-quanti-
tative RT-PCR analysis was performed to measure the expression level
of PGC-1a, glucose-6-phosphatase (G6Pase), carnitine palmitoyltrans-
ferase I (CPTI) and cytochrome c (Cyt. c) mRNA in HepG2 cells 2
days post-infection. b-Actin transcripts were used as control for the
amount of cDNA present in each sample. (b) Trypan blue exclusion
analysis of the proliferation of control Ad-GFP-infected and Ad-PGC-
1a-overexpressing HepG2 cells. (c) Western blot analysis of cyclin D1
expression in 3 days post-infection HepG2 cells.
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cells was aﬀected. As shown in Fig. 3, PGC-1a overexpressing
cells showed a 4-fold decrease in their migration ability
compared to control cells, conﬁrming the prediction that
PGC-1a upregulation could modulate the mobility of HepG2
cells.
3.4. PGC-1a activates E-cadherin expression in HepG2 cells
Among genes involved in cancer and cellular movement, we
noted that CDH1 which encodes E-cadherin is a potential
target for PGC-1a in HepG2 cells. To verify this possibility,
both semi-quantitative (Fig. 4a) and quantitative (real-time)
(Fig. 4b) RT-PCR analyses were performed. An up to 5-fold
increase in E-cadherin RNA levels was detected in cells
infected by Ad-PGC-1a. Accordingly, protein levels of E-cad-
herin in these cells were also markedly increased in a PGC-1adose-dependent manner (Fig. 4c). To ascertain that E-cadherin
upregulation in Ad-PGC-1a-transduced cells was mainly due
to an overexpression of this transcription coactivator, we
knocked down PGC-1a expression using its antisense RNA
and analyzed E-cadherin protein levels subsequently. Indeed,
a dose-dependent reduction of both E-cadherin and cyto-
chrome c was observed in PGC-1a overexpressing cells trans-
duced with the gene encoding its antisense RNA (Fig. 4d).
Fluorescence microscopy was also used to examine the corre-
lation between E-cadherin and PGC-1a protein expression in
HepG2 cells. High transduction eﬃciency (more than 80%)
of adenovirus infection in these cells was clearly observed
(Fig. 5a). In agreement with our Western blotting results,
E-cadherin signal in HepG2 cells was signiﬁcantly increased
after they were infected with Ad-PGC-1a (Fig. 5b). Moreover,
confocal imaging showed a simultaneous increase of nuclear
PGC-1a and membrane E-cadherin signals in infected HepG2
cells (Fig. 5c).
3.5. PGC-1a increases E-cadherin promoter activity
Since E-cadherin RNA levels in HepG2 cells were greatly
increased by PGC-1a overexpression, we further determined
whether E-cadherin promoter could be activated by this cofac-
tor. According to our transient cotransfection assays, reporter
expression driven by an E-cadherin promoter (1001 to +67)
was stimulated by PGC-1a in a dose-dependent manner
(Fig. 6a). To identify the cis-element(s) in E-cadherin promoter
responsible for its activation by PGC-1a, plasmids carrying a
SEAP reporter gene directed by serial deletion mutants of this
promoter were constructed and were co-transfected respec-
tively with a PGC-1a-expressing vector. A putative PGC-1a
responsive element might reside in the minimal E-cadherin
promoter (70 to +67) since no signiﬁcant diﬀerence in
relative induction (3-fold) by PGC-1a was detected when
reporter expression were driven by this and other longer
promoter fragments (Fig. 6b). To further elucidate the mole-
cular mechanisms underlying PGC-1a-activated E-cadherin
transcription, chromatin modiﬁcation nearby its proximal pro-
moter induced by PGC-1a in HepG2 cells was analyzed by
chromatin-immunoprecipitation (ChIP) assay. As shown in
Fig. 6c, more acetylated histone H3 molecules were associated
with E-cadherin proximal promoter in PGC-1a-overexpressing
HepG2 cells, suggesting that this coactivator might increase
the accessibility of basal transcription machinery to this region
by facilitating histone acetylation.4. Discussion
In this article, we, for the ﬁrst time, provided clear evidence
that overexpression of PGC-1a in HepG2 cells resulted in tran-
scriptional up-regulation of E-cadherin which might account
for their reduced migration ability.
Cell adhesion molecules (CAMs) such as E-cadherin and
carcinoembryonic antigen-related CAM family proteins
(CEACAMs) play an important role in intercellular-adhesion
and intracellular signaling for regulating cell morphology
and movement [23,24]. E-cadherin relies on diﬀerent catenins
(a-, b-, c-, p120-catenin) to connect with the actin cytoskeleton
to form adherens junction [14] whose destabilization was
reported to be associated with an increase of the invasive prop-
erties of HepG2 cells [25]. Once dissociated from E-cadherin
Fig. 2. Diﬀerential expression of gene sets in PGC-1a-overexpressed HepG2 cells. (a) Energy homeostasis associated genes. (b) Genes involved in
cancer and cellular movement. Two independent experiments were performed ( genes upregulated with ratio >2.0; genes down-regulated with
ratio <0.5).
Fig. 3. Cell migration ability was reduced by PGC-1a overexpression in HepG2 cells. Transwell cell migration analysis was performed using 50 ng/ml
HGF as the chemoattractant. Cells on the bottom of the insert membrane were ﬁxed then stained with 0.1% Giemsa. For quantiﬁcation, the average
number of migrated cells per ﬁeld was assessed by counting ﬁve random ﬁelds. **P < 0.01 when compared with control cells by Students t-test.
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Fig. 4. PGC-1a overexpression upregulated E-cadherin expression in HepG2 cells. (a) Semi-quantitative RT-PCR analysis of the level of the
expression of PGC-1a and E-cadherin mRNA. (b) Real time quantitative RT-PCR analysis of the expression of E-cadherin mRNA in HepG2 cells.
**P < 0.01. (c) Western blot analysis of the dose-dependent PGC-1a, E-cadherin and cytochrome c expression. Total protein was extracted 3 days
post-infection, probed with respective primary antibodies. Lane 1: non-infected control cells, lanes 2 and 3: Ad-GFP infected (multiplicity of
infection (MOI) = 150 and 500) cells, lanes 4–7: Ad-PGC-1a infected (MOI = 50, 150, 300, and 500) cells. (d) Examination of the eﬀects upon PGC-
1a silencing by Ad-antisense-PGC-1a recombinant virus in Ad-PGC-1a overexpressed HepG2 cells. The left panel shows non-infected and Ad-GFP
infected control cells, respectively; right panel indicated Ad-PGC-1a infected cells and PGC-1a-overexpressing cells re-infected with Ad-antisense-
PGC-1a for 2, 4, and 6 days, respectively. The mean relative signal intensity, normalized against protein loading control (b-actin) by densitometric
scanning, is shown below. Western blot analysis was performed twice with completely independent samples and the ﬁgure is one representative result.
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translocate into nucleus to activate the expression of genes cru-
cial for cell proliferation such as c-myc and cyclin D1 [26];
Hence, upregulated E-cadherin, by sequestering b-catenin to
form more adherens junctions, might be the main reason for
decreased migration of PGC-1a-overexpressing HepG2 cells
(Fig. 3). Our observations of a decreased cyclin D1 expression
and a slight growth reduction in these cells (Fig. 1b and c) fur-
ther supported above speculation.
Up-regulation of E-cadherin expression in breast and pros-
tate cancer cells has been proposed to be mediated by PPARc
[12,13]. In addition, the PPARc/PGC-1a pathway has been
postulated to play an important role in maintaining the expres-
sion of E-cadherin in lobular breast carcinoma [18]. In ourpreliminary study of 23 paired tumor and non-tumor samples
from HCC patients, decreased mRNA expression of E-cad-
herin (15/23) and PGC-1a (12/23) were observed in HCCs
and the expression of these two genes decreased concomitantly
in 10/23 HCC samples (data not shown). However, the precise
role of PGC-1a in regulation of E-cadherin expression has
not yet been delineated. Here, we not only demonstrated a
signiﬁcantly increase of E-cadherin mRNA level by PGC-1a
(Fig. 4a and b), but also showed a PGC-1a dose-dependent
increase of its protein levels in HepG2 cells (Fig. 4c). More-
over, a progressive decrease of E-cadherin protein was
observed in these cells when PGC-1a overexpression was
knockdown by its antisense RNA. Interestingly, the rate of
E-cadherin decrease was much slower than that of PGC-1a
Fig. 5. Immunoﬂuorescence-staining and confocal imaging of increased E-cadherin in HepG2 cells. (a) Fluorescence microscope imaging of GFP
expression in Ad-GFP infected HepG2 cells. Bright-ﬁle (Upper); GFP ﬂuorescent-visualization (Lower). (b) Immunoﬂuorescence staining of
E-cadherin protein expression in HepG2 cells with PGC-1a overexpression compared with the control Ad-GFP infected cells. Nuclei stained with
Hoechst 33258 (Upper); E-cadherin staining visible with rhodamine-labeled anti-mouse IgG antibody (Lower). (c) Confocal imaging analysis of
double immunoﬂuorescence staining in Ad-PGC-1a infected HepG2 cells (MOI 50) stained for PGC-1a (green) and E-cadherin (red).
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much lower turnover rate. These results together emphasized
that PGC-1a plays a positive role in modulating E-cadherin
transcription.
PGC-1a activates gene expression usually by docking to spe-
ciﬁc nuclear receptors, recruiting HAT-containing proteins
and assembling of multiple transcription complexes [9,10].
Besides up-regulating E-cadherin promoter activity in a dose-
dependent manner (Fig. 6a), PGC-1a also activated its mini-
mal promoter (70 to +67) (Fig. 6b). Since no typical PPARs
response element (PPRE) was present in this region, its activa-
tion by PGC-1a might be through PPARc-stimulated transac-
tivity of speciﬁcity protein-1 [27] because E-cadherin minimal
promoter contains two putative binding sites for this transcrip-
tion factor. On the other hand, results from our pilot study
indicated PPARc agonist troglitazone can upregulate E-cad-
herin expression in HepG2 cells at the transcriptional level
but only slightly increased the PGC-1a upregulated E-cadherin
promoter activity (data not shown). In the mean time, E-cad-
herin transcription has been reported to be up-regulated
through chromatin structural change due to histone acetyla-
tion [28] and this notion was further supported by our present
ﬁnding that E-cadherin transcription as well as the association
of acetylated histone H3 molecules with its 5 0-proximal
promoter were stimulated by PGC-1a overexpression inHepG2 cells (Fig. 6c). Interestingly, a recent study has demon-
strated that a combined treatment of PPARc agonist pioglitaz-
one and histone deacetylase inhibitor valproic acid not only
up-regulated E-cadherin expression but also inhibited the
growth and invasion of prostate cancer cells [12]. Taken
together, both PPARc and HAT-containing proteins could
serve as the nuclear partners for PGC-1a to activate E-cad-
herin transcription.
It is known that transcriptional repressor Snail has an
inverse relation with E-cadherin expression and invasive ability
in diﬀerent kinds of tumors including HCC [29]. Down-regula-
tion of Snail was associated with up-regulation of E-cadherin
expression in HepG2 and Hep3B hepatoma cell lines [30].
The involvement of Snail in PGC-1a-induced expression of
E-cadherin in HepG2 cells was ruled out because Snail mRNA
levels in these cells were not altered by PGC-1a overexpres-
sion. In addition, E-cadherin minimal promoter carrying a
mutated Snail binding element (E-box) was still activated fur-
ther supported our conclusion that Snail has only limited role
in the regulation of E-cadherin in these PGC-1a-overexpress-
ing HepG2 cells (data not shown).
Finally, it is also possible that the tumor suppressive eﬀects
of PGC-1a in HepG2 cells might be attributed to its ability to
reduce reactive oxygen species (ROS) levels by up-regulating
some mitochondrial antioxidant components such as uncou-
Fig. 6. PGC-1a transactivated E-cadherin mRNA expression in HepG2 cells. (a) One microgram of each pcDNA-HA-PGC-1a diluents eﬀector
plasmid, 0.1 lg of the reporter construct, and 0.1 lg of pCMV-LacZ reference plasmid were transiently co-transfected into HepG2 cells. SEAP
activity was determined 2 days post-transfection and normalized with reference to the respective b-galactosidase activities. *P < 0.05, **P < 0.01 when
compared with pcDNA3.1 vector only transfectant. (b) Each serial deletion mutant reporter constructs were cotransfected with either pcDNA3.1
control vector or pcDNA-HA-PGC-1a. SEAP activity was determined as described in methods. (c) Acetylated-histone H3 associated chromatin was
immunoprecipitated from infected HepG2 cells and precipitated E-cadherin 5 0-proximal promoter region (192 to +9) was ampliﬁed by PCR.
Immunoprecipitated without antibody (No Ab.) group served as negative control and input panel shows the equal loading of chromatin.
H.-J. Lee et al. / FEBS Letters 582 (2008) 627–634 633pling proteins and manganese superoxide dismutase [31]. ROS
have been shown to be critical for the epithelial-mesenchymal
transition (EMT) of tumor cells where decreased cellular adhe-
sion, reduced E-cadherin expression and increased migration
were often observed [32,33]. More interestingly, the endoge-
nous hydrogen peroxide levels in HepG2 cells were signiﬁ-
cantly higher than other hepatoma cell lines [34], suggesting
that the tumorigenicity of these cells might be reduced more
markedly by decrease their intracellular ROS levels. Questions
regarding the involvement of ROS in regulating E-cadherin
expression as well as other transformation phenotypes in bothparental and PGC-1a-overexpressing HepG2 cells are cur-
rently under investigation in our laboratory.
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